Un-Audited Financial Results for quarter ended on 30th September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The company (recently renamed from Kapil Cotex Ltd to Skybiotech Healthcare Ltd on November 7, 2025) reported consolidated revenue from operations of Rs. 191.65 lakhs for Q2 FY26, up about 19.5% from Rs. 160.36 lakhs in Q2 FY25. For H1 FY26, consolidated revenue rose to Rs. 430.47 lakhs from Rs. 351.21 lakhs, a growth of roughly 22.6% year-on-year. However, the company reported a consolidated net loss of Rs. 24.75 lakhs for the quarter and Rs. 89.18 lakhs for the half year, deepening from a loss of Rs. 30.97 lakhs in H1 FY25. The standalone parent has minimal activity (Q2 revenue just Rs. 1.54 lakhs), with the real operations coming from subsidiary Skybiotech Life Sciences Pvt Ltd (Q2 revenue Rs. 194.09 lakhs, net loss Rs. 32.14 lakhs). Operating cash flow turned negative at Rs. (1.86) lakhs versus a positive Rs. 48.30 lakhs in H1 FY25.
Despite top-line growth, widening consolidated losses and negative operating cash flow raise concerns about the company's path to profitability. Retail investors should note the recent name change signals a strategic pivot from textiles to healthcare/biotech, but the subsidiary is still loss-making, making this a high-risk turnaround story rather than an established performer.